
IRLAB

Q3.2026
Interim report
January – September 2026

IRLAB issues all its reports in Swedish language and this report has been translated into English. In the event of differences between the two, the Swedish version shall apply.



ERIK WERNER, works on developing machine learning and AI methods for analyzing the data generated as part of the ISP.

"IRLAB has built one of the broadest development portfolios in Parkinson's disease through its AI-based research platform, ISP, and we are now sharpening our focus on realizing the value created by this portfolio."

KRISTINA TORFGÅRD, CEO

Interim report January–September 2026

Highlights during the period and after

The U.S. Patent and Trademark Office intends to grant a patent for the drug candidate IRL1117.

Kristina Torfgård announced that she will step down from her position during the first quarter of 2027.

Janne Backman was appointed new chairman of the board of IRLAB.

IRLAB strengthens its focus on revenue generation and reduces its cost base.

Financial summary

SEK thousand	Jul–Sep 2026	Jul–Sep 2025	Jan–Sep 2026	Jan–Sep 2025	Jan–Dec 2025
Net sales	6,932	18,846	52,696	42,739	57,462
Operating profit	–12,944	–17,171	–18,919	–71,537	–93,398
Earnings per share before and after dilution, SEK	–0.09	–0.26	–0.22	–1.42	–1.64
Cash and cash equivalents	90,641	110,132	90,641	110,132	81,859
Cash flow from operating activities	–10,962	5,259	–53,086	–31,037	–55,220
Average number of employees	28	32	30	32	31
Share price at the end of period, SEK	1.83	2.92	1.83	2.92	1.97

Presentation for investors and media about the Q3 2026

Friday November 13, 2026, at 11:30 CET is the presentation of the Q3 interim report through a digital webcast. Access via link or view after the event:
https://youtube.com/live/BVyS3xkV3vU?feature=share

Financial calendar

IRLAB intends to publish financial reports and hold other corporate events in accordance with the following schedule:

Year-end Report Q4 2026	February 25, 2027
Annual report 2026	Week 16 2027
Interim report Q1 2027	May 6, 2027
Annual general meeting 2027	June 3, 2027
Interim report Q2 2027	August 26, 2027
Interim report Q3 2027	November 18,2027
Year-end Report Q4 2027	February 23, 2028

Interim reports are published on the Company's website, and updates regarding upcoming events are provided on an ongoing basis at the Company's website, www.irlab.se.



"By increasing our commercial focus and creating a more cost-efficient organization, we are strengthening our ability to translate the portfolio's significant potential into revenue-generating partnerships and long-term value creation."

KRISTINA TORFGÅRD, CEO

Comments from the CEO

During the quarter, we continued to strengthen our development portfolio. The progress of linepemat, from scientific publication to continued clinical development in collaboration with Otsuka, confirms the potential of our research platform and our ability to develop innovative drug candidates. For IRL1117, the announcement that the US Patent and Trademark Office (USPTO) intends to grant the project's first patent further strengthens its commercial potential and provides long-term intellectual property protection. In addition, we have now initiated the preclinical safety and toxicology studies, as well as the scale-up of drug substance manufacturing.

Through our AI-based research platform, ISP, we have built one of the world's broadest development portfolios in Parkinson's disease. At this stage, we believe that continued investment in generating new development programs would not create sufficient shareholder value. Consequently, following the reporting period, we announced our intention to focus resources on business development, strategic partnerships, and maximizing the value of our existing portfolio. Through a stronger commercial focus and a leaner, more cost-efficient organization, we aim to convert the portfolio's substantial potential into revenue-generating agreements and sustainable long-term value creation. The proposed organizational changes remain subject to consultations with employee representative organizations.

During the quarter, Janne Backman assumed the role of Chairman of the Board. Janne brings extensive experience in international business development and commercialization, which will be highly valuable as IRLAB advances its strategic priorities and continues its development. I have also informed the Board of my intention to step down as CEO during the first quarter of 2027. Until then, I will continue to work closely with the Board, management team, and employees to advance our business development efforts and create the best possible conditions for the company's continued success.

Linepemat – important progress toward the next milestone

During the quarter, the linepemat project reached an important scientific milestone with the publication of the preclinical research that formed the foundation for the drug candidate. The publication contributes to a greater understanding of its unique mechanism of action. Furthermore, the fact that the results have undergone independent peer review strengthens the project's scientific basis and serves as an important validation of its quality.

At the same time, recruitment continues in LIFT-PD, our Phase Ib study evaluating linepemat for the treatment of apathy in Parkinson's disease. Following the end of the quarter, we received the third and final milestone payment of USD 1 million related to the study, and we now look forward to the study results, which are expected in mid-2027.

Linepemat is being developed within the framework of our collaboration with Otsuka, which is funding the ongoing clinical study. The progress being made in the project confirms the strength of our research platform and our ability to develop innovative drug candidates for areas of significant unmet medical need. It also serves as a clear example of how our research can be translated into development programs that attract leading global pharmaceutical companies.

Apathy is one of the most debilitating symptoms of Parkinson's disease and other neurological disorders, yet there are currently no approved treatments available. For this reason, I believe that linepemat has significant commercial potential, while also having the potential to make a meaningful difference in the lives of patients and their families.

IRL1117 – patent decision strengthens the project's commercial potential

IRL1117 has the potential to transform the treatment of Parkinson's disease by addressing its core symptoms through a novel mechanism of action, without causing the long-term side effects often associated with current therapies. Our ambition is to develop an oral, once-daily therapy that can provide more consistent and sustained symptom control over time.

A significant milestone during the period was the announcement that the US Patent and Trademark Office (USPTO) intends to grant a patent for IRL1117. The patent has the potential to provide strong intellectual property protection in the world's largest pharmaceutical market, extending into the 2040s. This strengthens the project's commercial potential and further validates the innovation underpinning the drug candidate.

During the quarter, we continued preparations to advance IRL1117 into clinical development. The successful rights issue and overallotment option completed during the quarter have enabled us to take the next important steps in the development program, including the initiation of preclinical safety and toxicology studies and the scale-up of drug substance manufacturing. These activities are progressing according to plan and are critical to supporting a future application to initiate the first Phase I clinical trial.

IRL1117 is one of the most promising assets in our portfolio and exemplifies the productivity of our AI-based research platform, ISP. With a differentiated profile, strong patent position, and the potential to address a significant unmet medical need, we believe the project represents an attractive future partnering opportunity.

Focus on realizing the value of our project portfolio

The new integrated analysis of clinical data for mesdopetam, presented in August, has generated significant interest among potential partners and helped advance several licensing discussions. Based on pooled data from our Phase II studies, the analysis further strengthens the evidence that the drug candidate demonstrates clinically meaningful efficacy and a favorable safety profile.

IRLAB has built one of the broadest development portfolios in Parkinson's disease through its AI-based research platform, ISP, and is now sharpening its focus on realizing the value that has been created. The ongoing business development discussions regarding several of our drug candidates continue to reinforce our confidence in the portfolio's commercial potential.

Based on the ongoing dialogues, we continue to see strong opportunities to enter into commercially attractive agreements for several of our drug candidates, however, it is taking longer than anticipated. This reflects the complexity of generating revenues from promising development assets and underscores the need to further strengthen our business development efforts.

Following a strategic review, IRLAB has decided to concentrate the company's resources on business development, partnership activities, and continued value-enhancing work within its existing portfolio. As a result, we are planning to resize the organization and reduce our cost base. While this decision will unfortunately affect several highly valued employees, it is necessary to ensure that our resources are directed to the areas with the greatest potential to create value. At the same time, we are strengthening our commercial capabilities to better convert the portfolio's substantial potential into future partnerships and revenue-generating agreements. In parallel, we continue to review our overall cost base to identify and implement additional cost-saving measures.

The measures I have described above give us an organization that is better suited to what is now our main task: securing agreements and building long-term value from the scientific progress we have already achieved.

I would like to thank our employees for their professionalism, resilience, and dedication during a demanding period, as well as our shareholders and partners for their continued support and confidence in IRLAB.



Kristina Torfgård, CEO, IRLAB

Our strategic priorities:

- **Partnerships and financing** – continued and deepen discussions with potential collaborators, licensees, and investors to secure funding for development programs and support the company's long-term growth.
- **Linepemat (IRL757)** – execute the ongoing Phase Ib clinical study in close collaboration with Otsuka, evaluate the results and determine the strategy for the next stage in development.
- **Mesdopetam** – secure funding for the Phase III program through strategic partnerships or licensing agreements.
- **Pirepemat** – implement the long-term development strategy and prepare for the next clinical study.
- **IRL1117** – advance preclinical development activities with the goal of making the project Phase I-ready.

IRLAB's unique offering and position

IRLAB discovers and develops novel treatments to transform the life of patients living with Parkinson's and other CNS disorders. Rooted in Nobel Prize-winning research, IRLAB has grown rapidly to become recognized and respected as a world-leader in understanding the complex neuropharmacology of CNS disorders and especially Parkinson's. We have a welldefined, strategically focused R&D pipeline of powerful new treatments targeting various stages of Parkinson's. Having a full range of effective treatments for the disease's different complications and symptoms is regarded as essential by both the medical and patient communities and is at the same time potentially a possibility for a successful pharmaceutical business.

ISP – a pioneering research platform

IRLAB has deep profound understanding of Parkinson's based on research conducted by the research group of Nobel laureate Prof. Arvid Carlsson. IRLAB has a unique proprietary research platform – Integrative Screening Process (ISP) – that has generated all of the company's first-in-class drug candidates.

Focused strategy

Medicines developed by IRLAB should be able to treat people with Parkinson's throughout all stages of the disease. IRLAB has blockbuster potential as a pharma business.

Validated proof-of-concept

RLAB has validated its research and development strategy through its proven ability to generate novel drug candidates and advance them all the way to Phase III-ready development programs

Organization positioned for success


IRLAB is an organization with an experienced team. IRLAB is listed on the Nasdaq Stockholm main market (IRLAB A).

Broad and solid portfolio

IRLAB's portfolio comprises five unique drug candidates, each with blockbuster potential, generated by the world-unique ISP research platform.

IRLAB's portolio

"First-in-class" drug candidates to treat people with Parkinson's throughout all stages of disease.



* Currently no active clinical development in this indication.

** Supported by The Michael J. Fox Foundation and in collaboration with Otsuka.

R&D update



"During the quarter, we continued to advance several of our highest-priority programs. Recruitment into the clinical LIFT-PD study of linepemat continued to progress, while we further strengthened the program's scientific foundation through the publication in a peer-reviewed international scientific journal of the medicinal chemistry research that led to the selection of linepemat as the development candidate. In parallel, we made important progress in the preparatory and regulatory work required to advance IRL1117 into Phase I clinical development."

NICHOLAS WATERS, EVP AND HEAD OF R&D

About IRLAB's drug candidates

Mesdopetam

The goal for mesdopetam is to improve the quality of life for people living with Parkinson's and suffering from dyskinesia, a serious type of troublesome and involuntary movements that commonly occur after long-term levodopa treatment.

It is estimated that about 40 percent of all people treated for Parkinson's have dyskinesia, which corresponds to approximately 1.4–2.3 million people in the eight largest markets in the world (US, EU5, China and Japan). Of these individuals living with Parkinson's today, as many as 75% go untreated for their dyskinesia. Thus, most patients with dyskinesias are not treated with any specific anti-dyskinetic medication, as the alternative treatment strategies available either have insufficient efficacy or are not tolerated. Instead, levodopa dose adjustment is usually relied on, most often through dose reduction. This is then followed in severe cases by complex and expensive treatments based on surgical procedures for the implantation of pump-based infusion of levodopa, or surgical implantation of electrodes in the brain.

Mesdopetam specifically targets this large group of patients, without adequate pharmacological treatment, and has significant clinical and commercial potential to address this medical need.

Mesdopetam also has the potential to treat Parkinson's psychosis (PD-P), which affects approximately 1.5 million people in the eight largest markets worldwide. Furthermore, mesdopetam has the potential to treat other neurological diseases such as tardive dyskinesia, which represent an even larger market.

The successful Phase Ib, Phase IIa and Phase IIb studies in PD-LIDs showed a very good safety and tolerability profile and Proof-of-Concept with the potential for a full anti-dyskinetic effect in the majority of patients who do not respond to or tolerate current treatment strategies. The Phase IIb study indicated a dose-dependent anti-dyskinetic and anti-parkinsonian effect in combination with a tolerability and safety profile that does not differ from placebo in this particular group of patients.

Mesdopetam can thus treat dyskinesia and at the same time have a beneficial effect on other Parkinson's symptoms without causing more side effects than placebo, this in patients who do not have any alternative treatments today, which gives mesdopetam a unique and differentiated position in the global competition.

The agreement between the regulatory authorities FDA and EMA on the design of the Phase III program for mesdopetam, with two parallel efficacy studies with a three-month treatment period, followed by a 9 month open label extension for participants who wish to continue treatment and a parallel safety study, provides IRLAB with a Phase III program that can lead to market approval in both the US and Europe.

The market research conducted by external market access and pricing consultants company shows that mesdopetam has a very high potential to become an important treatment for the vast majority of individuals living with Parkinson's and levodopa-induced dyskinesias, who currently do not respond to, or tolerate, the available options.

Current status

The authorities in both the US and Europe consider that the

studies and data generated to date are adequate to advance the program into Phase III.

Their assessment is based on the completed preclinical studies, toxicology studies, CMC development and clinical studies from Phase I through Phase IIb. It has also been confirmed that the FDA, EMA and IRLAB have a common view regarding the design of the Phase III program studies and the key components for evaluating efficacy ("endpoints") and safety. The company has also obtained scientific advice from national European drug regulatory authorities in Germany (BfArM) and Portugal (Infarmed), in order to ensure that the mesdopetam development program also meets specific national requirements.

The Phase III program will include double-blind treatment with mesdopetam or placebo in approximately 300 patients for 3 months divided into two studies of approximately 150 patients/study that will be conducted in parallel, followed by a so-called Open Label Extension (OLE) for those patients who so wish. In parallel with the efficacy and OLE studies, a separate safety study of 6-12 months will be conducted. This is done to meet the FDA's requirement to achieve at least 100 patients treated with mesdopetam for one year, as well as to meet the general guidelines that indicate that a safety population should amount to 300-600 patients treated for 6 months.

During the past year, work has been carried out to develop the marketing strategy for mesdopetam, through structured interviews with healthcare organization leaders to better understand medical needs from the perspective of healthcare and those who finance healthcare. By gaining insight into the needs of patients, regulatory authorities and healthcare, the program has been designed so that the future medicine meets all expectations and requirements and can thereby become a successful and appreciated treatment.

During H1 2026 a market survey was concluded, this time with a group of neurologists with extensive clinical experience in treating patients with levodopa-induced dyskinesias (LIDs), and with responsibility for large groups of patients with Parkinson's disease. The results confirm that there is a significant unmet need for effective and safer treatment options for LIDs. Interest in mesdopetam was consistently high. The drug candidate's differentiated mechanism of action (dopamine D3 receptor antagonism) and its clinical profile were assessed as very advantageous over existing treatment strategies. The assessment was made based on efficacy, safety, tolerability and mesdopetam's simple dosing regimen, which together are perceived as a clear differentiation compared to existing treatments. A market access and pricing effort was conducted in Europe during the second quarter. The objective was to test the European pricing assumptions previously predicted now considering the evolving Health Technology Assessment (HTA) environment and changes in global pricing dynamics, including Most-Favored-Nation drug pricing policy (MFN). The conclusion from the study is that mesdopetam can achieve similarly high net prices in both the US and Europe without significant MFN risk.

An integrated analysis of clinical data for mesdopetam was presented at StanCon 2026 – the International Conference on Bayesian Inference and Probabilistic Programming. The analysis is based on pooled data from our randomized, placebo-controlled Phase IIa and Phase IIb studies and relies on analyses involving—and comparisons between—a wide range of Bayesian statistical models. While the numerical estimates of mesdopetam's anti-dyskinetic effects vary slightly, the conclusion is unequivocal: the analysis confirms mesdopetam's clinically relevant efficacy profile and its anti-dyskinetic effectiveness.During the past year, the company has been granted additional so-called "composition of matter" patents in Europe, the USA and during the period also in China. These patents provide exclusive patent protection for mesdopetam but also protect the process for its production. The granted patents expand the already strong patent protection for mesdopetam. There is therefore potential for market exclusivity towards 2044/2045 in the large and important markets. At the end of the year, the company received information that the European Patent Office (EPO) intends to grant an additional patent for mesdopetam. The new patent covers various forms of the salt of the drug candidate and expands the already strong intellectual property protection for mesdopetam and provides important additional protection for the drug candidate and its market exclusivity, with the possibility of extended exclusivity. Additional patent applications for mesdopetam have also been granted in China.

Pirepemat

Pirepemat (IRL752) has the potential to be the first in a new class of drugs designed to reduce falls and fall injuries in people living with Parkinson's. It does this by inhibiting 5HT7 and alpha2 receptors in the cerebral cortex, leading to increased dopamine and noradrenaline levels in this brain region, an effect that cannot be achieved with the drugs currently prescribed for people living with Parkinson's

Falls are a serious consequence of Parkinson's and often lead to severe complications such as fractures, reduced mobility and reduced quality of life. Approximately 50 percent of all people treated for Parkinson's fall regularly, which means that approximately 2.6 million people suffer from a significantly reduced quality of life, also driven by the fear of falling. There are currently no treatments available despite the great medical need. The burden of falls on society is also significant. The cost of hospital care in the USA was estimated a few years ago at approximately USD 30,000 for a fall injury in a person over 65 years of age. The costs for society are also significant. In the USA alone, injuries related to falls in the elderly (>65 years of age) are estimated to cost up to USD 80 billion/year (doi: 10.1136/ip-2023-045023).

After completing successful Phase I studies, an exploratory Phase IIa study was conducted in 32 people with advanced Parkinson's and cognitive impairment, and the recently completed REACT-PD study indicates that pirepemat has the potential to reduce the risk of falls and, consequently, fall-related injuries.

Current status

The Phase IIb study (REACT-PD), which was completed in the beginning of 2025, evaluated the effect of pirepemat on fall frequency in Parkinson's patients over three months of treatment. Secondary objectives include cognitive and neuropsychiatric evaluations and continued studies of safety and tolerability.

The results showed that treatment with pirepemat (600 mg daily) reduces fall frequency by 42 percent in people with Parkinson's disease, but that the effect did not reach statistical significance compared to placebo. Additional results, based on

predefined analyses of efficacy data from the REACT-PD study, show that medium plasma concentrations of pirepemat reduce fall frequency by as much as 51.5% after three months of treatment. This effect is highly clinically meaningful and statistically significant ($p<0.05$ compared to placebo). A reduction in falls in Parkinson's is considered clinically meaningful if the reduction is approximately 20-25% (DOI:10.1016/j.parkreldis.2018.11.008).

In late December 2025, IRLAB's external scientific advisory board met to evaluate the results of the REACT-PD study and discuss the next steps in the pirepemat development program. The scientific council consists of four Key Opinion Leaders (KOLs) from North America, Europe and Scandinavia, recognized for their expertise in Parkinson's disease with a particular focus on falls, complications related to falls and the mechanisms leading to falls in Parkinson's.

The expert group believes that falls are a significant unmet medical need in Parkinson's disease and that there is a lack of available drug treatment. The group emphasized that falls are an important clinical indicator and should be the primary focus of future clinical trials with pirepemat. The reduction in falls observed in the REACT-PD trial by pirepemat was considered to be highly clinically meaningful. Furthermore, the pharmacological rationale and mechanism of action of pirepemat are consistent with the biphasic concentration-response profile observed in REACT-PD. The expert group concluded that pirepemat is a promising drug candidate that may provide meaningful therapeutic benefits and that further development is warranted.

Based on the promising results for the drug candidate and the advice provided by the expert group, a strengthened development plan is in place. The work includes continued development of the drug substance manufacturing method on a large scale as well as all preparations for the implementation of a clinical study with the goal of optimizing the titration of individual dosage so that all treated individuals fall within the effective therapeutic window. The results will be an important building block in the design of the future phase III program.

The strong interest was also confirmed at the international AD/PD conference in March 2026, where the results from REACT PD aroused great engagement and gave rise to continued and new dialogues.

More information about REACT-PD can be found on EudraCT: 2019-002627-16 and clinicaltrials.gov: NCT05258071.

Patents granting market exclusivity for pirepemat in all major markets, USA, Europe, Japan extend into the mid-2040s.

Linepemat

Linepemat aims to treat apathy in Parkinson's and other neurological diseases. Apathy is a disabling condition that affects over 10 million people in the US and an equal number in Europe. The prevalence is high and apathy is estimated to occur in 20–70 percent of people diagnosed with Parkinson's, representing 1.1–4.0 million people in the eight largest markets worldwide. Apathy also occurs in 43–59 percent of people diagnosed with Alzheimer's disease, representing 4.9–6.7 million people in the ten largest markets alone (France, Canada, China, Italy, Japan, Spain, the UK, South Korea, Germany and the US).

Linepemat has shown beneficial effects in several preclinical models of cognitive impairment and motivation. The effects of linepemat observed in these models are thought to be linked to linepemat's ability to counteract the attenuation of neural signaling from the cerebral cortex to deeper brain regions, a mechanism that has been proposed to underlie apathy in neurological diseases.

Current status

The development program for linepemat is fully funded through so-called "signal-finding" studies in patients with Parkinson's and apathy. The development program has been funded through a research grant from The Michael J. Fox Foundation and a collaborative agreement with the global pharmaceutical company Otsuka.

During the previous year, we have successfully completed the preclinical safety and toxicology studies, Phase I clinical studies for linepemat. These results formed the basis for the submission of an application for approval to conduct a larger clinical study of linepemat in patients with Parkinson's and apathy.

The results from the preclinical and clinical Phase I studies show that linepemat is well absorbed, provides good exposure in the body and has a good tolerability and safety profile. Overall, safety, tolerability and pharmacokinetic profile support the continued development of IRL757.

Following EMA approval to conduct LIFT-PD, a clinical trial of linepemat in people living with Parkinson and apathy has been activated at clinics across Europe. Screening of study participants began in January 2026, and the first patients were randomized to treatment with linepemat or placebo in February. Recruitment is progressing, with the first results expected in mid-2027.

During the summer, the World Health Organization (WHO) announced that IRL757 had been assigned the generic name linepemat—an acknowledgment that the substance possesses a unique pharmacological profile and constitutes a unique pharmaceutical entity. Linepemat is now recognized globally and is available for use by researchers and healthcare professionals, as well as in future pharmaceutical products. Moving forward, the name linepemat will be used in all communications.

During the quarter, an important scientific milestone was achieved through the publication in Bioorganic & Medicinal Chemistry Letters of the preclinical research that resulted in the identification of linepemat. The publication strengthens the scientific foundation of the drug candidate through independent peer review of the methods and results.

IRL942

Approximately 12 percent of people aged 65 and older experience cognitive decline, which greatly affects their quality of life. The condition is even more common in people living with neurological diseases.

Impaired nerve signaling in the cerebral cortex is believed to be a cause of cognitive impairment and neuropsychiatric symptoms in Parkinson's and other neurological diseases.

IRL942 has a unique ability to enhance frontal cortex nerve signaling, activate genes important for the function of neural connections and the associated neural pathways in the cerebral cortex, which counteracts impaired cognitive function. This has been shown in several different preclinical models of impaired cognitive function.

IRL942 could thus become a drug that can improve cognitive

function in the 1.5 million people treated for Parkinson's and the 3 million people treated for Alzheimer's, estimated in the ten largest markets

Current status

The development of GMP manufacturing of the drug substance and the development of the drug product, i.e. the pharmaceutical formulation, have been completed. The development pace for IRL942 has been reduced, resulting in the completion of the preclinical regulatory toxicology and safety studies required to begin Phase I clinical development not earlier than during 2027.

IRL1117

Treatment with IRL1117 leads to potent dopamine D1 and D2 receptor activation, which in preclinical studies has shown full anti-Parkinson effect, rapid onset and more than 24 hours of sustained effect. The goal of the drug candidate IRL1117 is an orally administered drug for the treatment of the core symptoms of Parkinson's disease that should be taken once a day.

People with Parkinson's disease are currently prescribed the anti-Parkinson's treatment levodopa, which treats the core symptoms of the disease, tremor, rigidity and bradykinesia (slow movements). Levodopa has been the standard treatment for Parkinson's since the 1960s and is currently the only medication that provides symptomatic relief of the disease throughout its progression.

However, levodopa has significant treatment-related limitations, especially the short duration of action and the occurrence of treatment-related complications in the form of fluctuations in treatment effect and excessive involuntary movements. Compared to levodopa treatment, IRL1117 differs significantly because in preclinical studies it has higher potency and shows a full anti-Parkinsonian effect in long-term treatment, dosed only once a day, without causing the troublesome complications that occur with long-term treatment with levodopa.

These complications are linked to the activation of certain genes in the brain areas affected by Parkinson's. In animal studies completed in the second quarter comparing the effects of IRL1117 and levodopa, the results show that IRL1117 provides full anti-Parkinson's effect without activating these genes and does not cause complications. Levodopa, on the other hand, activates these genes and leads to known complications. The study thus clarifies the advantage of treatment with IRL1117 compared to levodopa.

As a potentially better alternative to levodopa, IRL1117 could be administered to all people currently being treated for Parkinson's, i.e. up to 5.7 million people in the eight largest markets.

Current status

The development work with IRL1117 is ongoing. The preclinical results in long-term treatment show that IRL1117 has full anti-Parkinson effect and at the same time does not cause well-known complications, such as severe fluctuations in effect, that occur in long-term treatment with levodopa. The results are very promising and indicate that IRL1117 has the potential to significantly improve the basic treatment of Parkinson's.

In parallel, the method development for substance manufacturing on a larger scale (CMC work) is underway. We are now working on optimizing the method for GMP syntheses to manufacture the amount of substance required for the implementation of the preclinical regulatory safety and toxicological studies that are necessary for the start of Phase I.

During previous period, an external laboratory has conducted additional studies with IRL1117. The studies verify, among other things, important safety aspects, the long-term effect of IRL1117 and contribute with additional DMPK data supporting for the upcoming application for the implementation of Phase I studies.

During the quarter, we continued to prepare IRL1117 for clinical development. The next important steps in the development program are to initiate preparatory studies ahead of the planned preclinical safety and toxicology studies, as well as to scale up the manufacturing of the drug substance. This work is progressing according to plan and is critical to enabling the submission of an application to initiate the first Phase I clinical studies.

A significant milestone during the period was the notification from the US Patent and Trademark Office (USPTO) of its intention to grant a patent for IRL1117. The patent has the potential to provide strong intellectual property protection in the world's largest pharmaceutical market, extending into the 2040s.

Integrative Screening Process (ISP)

IRLAB's portfolio is generated with the unique proprietary drug discovery platform Integrative Screening Process, called ISP, which has proven to enable the discovery of truly novel first-in-class compounds. The ISP methodology combines systems biology screening models, an extensive database, and modern machine learning-based analytical methods. This means that IRLAB obtains unique insights into the overall effect of the studied molecules at an early stage.

The platform can already at the discovery phase predict the drug candidates with the greatest potential in a certain indication, as well as the lowest technical risks. ISP provides an improvement in probability of drug discovery success in clinical phase transition, compared with industry standard. This is also exemplified by higher probability to demonstrate clinical proof-of-concept in patients and reach later stages of clinical development for an ISP generated drug candidate compared with industry standard.

Our discovery and development strategy provides IRLAB with a strong competitive advantage in the discovery of novel treatments for Parkinson's and other CNS disorders. It is important to IRLAB to constantly refine and develop this technology-base to remain at the forefront of modern drug discovery. A close cooperation with universities and academic researchers also contributes to IRLAB being able to keep leading the development of cutting-edge technology.

Current status

In early 2026, a collaboration was initiated with the Danish biotechnology company Biomia ApS, where IRLAB's research platform is used to evaluate Biomia's drug candidates. Through this collaboration, we applied IRLAB's extensive expertise in the development of new treatments for CNS diseases. The collaboration with Biomia represents a natural step for IRLAB to utilize the ISP platform in CNS diseases outside of Parkinson's.

The group's performance January – September 2026

IRLAB Therapeutics AB, corporate identity number 556931-4692, is the parent company in a group that carries out research and development with the aim of transforming life for people with Parkinson's and other CNS disorders through novel treatments. The parent company's operations mainly consist of providing management and administrative services to the group's operating companies, and activities related to the stock market. The research and development operations are conducted in the wholly owned subsidiary Integrative Research Laboratories Sweden AB. IRLAB has offices in Gothenburg (main) and Stockholm, Sweden.

Revenues

The Group's revenue for the period January 1 - September 30 2026 amounted to SEK 57,066k (48,262), of this amount, SEK 52,696k (42,739) represents net sales, consisting of a milestone payment from Otsuka of USD 3 million, corresponding to SEK 27,101k, and service revenues of SEK 25,595k. The remaining amount comprises other income, consisting of foreign exchange effects in 2026 and a grant from the Michael J. Fox Foundation in 2025.

Research and development costs

For the period January 1 - September 30, 2026 the total costs for research and development amounted to SEK -60,417k (-99,774), corresponding to 80 percent (83) of the group's total operating expenses. Development costs vary over time, depending on where in the development phase the projects are.

Operating expenses

The Group's operating expenses amounted for the period January 1 - September 30, 2026 to SEK -75,986k (-119,800), and for the third quarter of 2026 to SEK -22,806k (-37,574).

Other external costs

Other external costs for the period January 1 - September 30, 2026 amounted to SEK -42,728k (-77,998), and for the third quarter of 2026 to SEK -12,436k (-26,878). Expenses were lower compared with the corresponding period of the previous year, primarily attributable to lower levels of clinical trial activity and the impact of implemented cost-saving measures.

Personnel costs

Personnel costs amounted to SEK -30,173k (-33,379) for the period January 1 - September 30, 2026, and for the third quarter of 2026 to SEK -9,354k (-9,387). Personnel expenses decreased compared with the previous year, primarily as a result of the voluntary reduction in working hours agreed by employees during the first half of 2026, as well as a reduction in headcount of three employees during the third quarter.

Depreciation

Depreciation amounted to SEK -3,085k (-3,276) for the period January 1 – September 30, 2026.

Financial Items

Financial income for the period January 1 – September 30 2026 amounted to SEK 880k (952) and consists of interest income.

Financial expenses for the period January 1 - September 30, 2026 amounted to SEK -5,224k (-15,932). In addition to interest expenses, these costs comprise transaction and arrangement costs, as well as a modification gain of SEK 462k, which has been recognized on a net basis against the interest effect, transaction costs and arrangement costs, relating to the loan from Fenja Capital ("Fenja"), amounting to SEK -1,692 thousand (-4,706). The lower financial expenses are attributable to the repayment and set-off of loan liabilities in connection with the rights issues completed in June 2025 and June 2026.

Result for the period

The result for the period January 1 – September 30, 2026 amounted to SEK -23,264k (-86,518).

The company has no tax costs since there is no profit.

Equity

Equity in the Group amounted to SEK 80,163k (54,210) on September 30, 2026 and the equity ratio was 52 (32) percent. Equity in the Parent Company amounted to SEK 383,331k (389,611) and the equity ratio was 94 (93) percent.

Financial position & Cash flow

Cash and cash equivalents

The Group's cash and cash equivalents, including cash and bank accounts, amounted to SEK 90,641k (110,132) at the end of the period. No cash or cash equivalents of the Group were pledged as security in 2026 or 2025.

Cash flow

Cash flow from operating activities amounted to SEK -53,086k (-31,037) during the period January 1 - September 30, 2026.

Cash flow from investing activities amounted to SEK 0k (0) during the period January 1 - September 30, 2026.

Cash flow from financing activities amounted to SEK 58,850k (74,252) during the period January 1 - September 30, 2026.

The cash flow during the period January 1 - September 30, 2026. amounted to SEK 5,764k (43,215). In the reports for the first and second quarters of 2025, a portion of the interest expense was incorrectly presented as affecting cash flows. This has been corrected, and the adjustment is reflected in the cash flow statement in the third-quarter 2025 report.

During June and July, the Company completed a rights issue and a subsequent over-allotment issue. The rights issue was oversubscribed by approximately 112.6%, and the Board of Directors exercised the over-allotment option in full. The rights issue raised gross proceeds of approximately SEK 68 million, while the over-allotment issue contributed a further SEK 8.6 million, resulting in aggregate gross proceeds of

approximately SEK 76.5 million, before deduction of transaction costs.

In connection with the rights issue, the Company amortized SEK 5.2 million of the outstanding loan and renegotiated the loan agreement with Fenja, whereby the maturity date of the remaining SEK 18.5 million of the approximately SEK 23.7 million outstanding loan was extended from 30 October 2026 to 30 November 2027.

In connection with the renegotiation of the loan from Fenja, the previously issued warrants were replaced with new warrants entitling Fenja to subscribe for Class A shares at a subscription price of SEK 1.68 per share. The number of warrants corresponds to a dilution effect of three percent in relation to the number of shares in the Company following completion of the above-mentioned rights issue. The warrants remain outstanding until 30 April 2031. The arrangement fee related to the renegotiation of the loan from Fenja was recognized as a finance cost in June 2026. During the third quarter, the carrying amount of the loan liability was adjusted to its new present value, calculated using the original effective interest rate. The resulting difference of SEK 462k was recognized as a modification gain within finance income.

The value of the issued warrants is recognized as a non-cash interest expense allocated over the term of the loan. Correspondingly, the liability to Fenja will increase over the life of the facility, such that the loan amount at maturity will equal SEK 18.5 million. The amended loan agreement became effective in connection with the completion of the rights issue, which took place in July 2026. The rights issue was registered and paid for in July 2026. The overallotment issue was partially registered and partially settled in July and August 2026.

The issue was fully settled in August 2026, and IRLAB received approximately SEK 67 million in net proceeds after transaction costs and taking into account the repayment made to Fenja Capital.

Investments

No investments were made by the Group in the first half of 2026 or 2025. Most expenditures relate to research and development and are expensed as incurred. The Company has no ongoing or planned tangible investments.

Financial position

IRLAB is a research and development company with no regular income. The company is primarily financed via the capital market or through the sale or out-licensing of projects, with an initial payment at signing of the agreement, as another financing option. In addition to revenues from operations, the financing strategy is based on continually ensuring that the company is adequately financed through the capital market to effectively run the operations and make rational business decisions.

The Group continuously works to secure funding for its operations. Given the Company's current financial position, the Board of Directors and the Chief Executive Officer believe that there are uncertainties that may cast doubt on the Company's ability to continue as a going concern. To meet its future financing needs, the Company is actively engaged in initiatives aimed at securing collaborations, licensing arrangements, or additional funding through capital markets transactions.

The IRLAB share

IRLAB's Class A share has been listed on Nasdaq Stockholm's main list since September 30, 2020.

Share capital, number of shares and voting rights

At the end of the period, the registered share capital of IRLAB amounted to SEK 2,974,238, divided into a total of 148,711,921 shares with a quota value of SEK 0.02 per share. There are 148,632,145 Class A shares and 79,776 Class B shares. All shares, including Class B shares, carry one vote each.

Warrants Programmes

Directed Issue of Warrants to Fenja Capital II A/S.

The Annual General Meeting held on June 30, 2026 resolved on a directed issue of warrants to Fenja Capital in accordance with the loan agreement entered into between the Company and Fenja Capital in May, 2026, which became effective in July, 2026.

Fenja Capital II A/S subscribed for 4,599,337 warrants of series 2026/2031 in the Company in July 2026. The warrants were issued free of charge. Each (1) warrant entitles the holder to subscribe for one (1) new Class A ordinary share in the Company at a subscription price of SEK 1.68 per share. The subscription price was determined through arm's-length negotiations.

Subscription for new Class A ordinary shares by exercise of the warrants may take place from July, 2026 up to and including April 30, 2031. Upon full exercise of the warrants, the share capital may increase by a maximum of SEK 104,964.96.

Share-Based incentive Programme for the board of directors 2026/2029:1

The Annual General Meeting held on June 30, 2026 resolved to establish a warrant programme for members of the Board of Directors of IRLAB with a term of approximately three (3) years. Each warrant entitles the holder to subscribe for one (1) new Class A ordinary share during the period from September 1, 2029 up to and including September 29, 2029.

The fair value of the warrants was calculated and determined by an independent third party using the Black-Scholes valuation model and amounted to SEK 0.1798 per warrant. The subscription price for shares subscribed for pursuant to the warrants was set at SEK 2.63 per Class A ordinary share.

Three Board members subscribed for a total of 1,110,000 warrants of series 2026/2029:1 in July 2026 and paid warrant premiums amounting to SEK 198 thousand in aggregate. Upon full exercise, the warrants would correspond to a dilution of approximately 0.8%. Full exercise of the subscribed warrants would result in an increase in the Company's share capital of up to SEK 22,000.00.

Consolidated income statement in summary

Amounts in SEK thousand	2026 Jul–Sep	2025 Jul–Sep	2026 Jan–Sep	2025 Jan–Sep	2025 Jan–Dec
Operating income					
Net revenue	6,932	18,846	52,696	42,739	57,462
Other operating income	2,930	1,557	4,370	5,524	5,335
Total income	*9,862*	*20,404*	*57,066*	*48,262*	*62,797*
Operating expenses					
Other external costs	-12,436	-26,878	-42,728	-77,998	-99,375
Personnel costs	-9,354	-9,387	-30,173	-33,379	-46,116
Depreciation of intangible and tangible fixed assets	-1,016	-1,043	-3,085	-3,276	-4,319
Other operating cost	-	-266	-	-5,146	-6,384
Total operating expenses	*-22,806*	*-37,574*	*-75,986*	*-119,800*	*-156,195*
Operating result	**-12,944**	**-17,171**	**-18,919**	**-71,537**	**-93,398**
Result from financial items					
Financial income	326	315	880	952	1,375
Financial costs	-530	-3,378	-5,224	-15,932	-17,987
Total financial items	*-203*	*-3,063*	*-4,344*	*-14,981*	*-16,612*
Result after financial items	**-13,148**	**-20,234**	**-23,264**	**-86,518**	**-110,010**
Tax on income	-	-	-	-	-
Result for the period	**-13,148**	**-20,234**	**-23,264**	**-86,518**	**-110,010**
Earnings per share before and after dilution (SEK)	-0.09	-0.26	-0.22	-1.42	-1.64
Average number of shares, before and after dilution	142,619,909	78,827,330	104,376,605	60,953,465	66,998,887
Number of shares at end of period	148,711,921	84,938,020	148,711,921	84,938,020	84,938,020

Profit/loss for the period is entirely attributable to the parent company's shareholders.

Consolidated statement of comprehensive income in summary

Amounts in SEK thousand	2026 Jul–Sep	2025 Jul–Sep	2026 Jan–Sep	2025 Jan–Sep	2025 Jan–Dec
Result for the period	–13,148	–20,234	–23,264	–86,518	-110,010
Other comprehensive income	-	-	-	-	-
Total result for the period	**-13,148**	**–20,234**	**-23,264**	**-86,518**	**-110,010**

Consolidated statement of financial position in summary

Amounts in SEK thousand	09/30/2026	09/30/2025	12/31/2025
ASSETS			
Fixed assets			
Intangible fixed assets	46,862	46,862	46,862
Tangible fixed assets	2,389	6,516	5,474
Total fixed assets	**49,251**	**53,378**	**52,335**
Current assets			
Short-term receivables	13,969	7,549	6,610
Cash and cash equivalents	90,641	110,132	81,859
Total current assets	**104,610**	**117,681**	**88,468**
TOTAL ASSETS	**153,862**	**171,060**	**140,804**
EQUITY AND LIABILITIES			
Equity			
Share capital	2,974	1,699	1,699
Other contributed capital	871,841	800,408	800,408
Retained earnings incl. results for the period	–794,652	–747,897	–771,389
Total equity	**80,163**	**54,210**	**30,718**
Long-term liabilities			
Interest bearing debt, loan	17,028	25,422	-
Interest bearing debt, leasing	-	907	-
Total long-term liabilities	**17,028**	**26,329**	**-**
Short-term liabilities			
Interest bearing debt, loan	-	-	26,416
Interest bearing debt, leasing	907	3,477	3,536
Other liabilities	55,765	87,044	80,134
Total short-term liabilities	**56,672**	**90,521**	**110,086**
TOTAL EQUITY AND LIABILITIES	**153,862**	**171,060**	**140,804**

Consolidated statement of changes in equity in summary

Amounts in SEK thousand	Share capital	Other contributed capital	Retained earnings incl. total comprehen-sive income for the period	Total equity
Equity January 1, 2025	**1,037**	**690,205**	**–658,608**	**32,635**
Rigts issue	661	115,082	-	115,743
Issue cost	-	-13,305	-	-13,305
Convertible effect	-		-2,771	-2,771
Warrant premium	-	8,427	-	8,427
Comprehensive income for the period	-	-	-86,518	-86,518
Equity September 30, 2025	**1,669**	**800,408**	**–747,897**	**54,210**
Comprehensive income for the period	-	-	-23,491	-23,491
Equity December 31, 2025	**1,699**	**800,408**	**–771,389**	**30,718**
Equity January 1, 2026	**1,699**	**800,408**	**–771,389**	**30,718**
Rigts issue	1,275	75,253	-	76,529
Issue cost	-	-4,018	-	-4,018
Proceeds from warrant premiums	-	198	-	198
Comprehensive income for the period	-	-	-23,264	-23,264
Equity September 30, 2026	**2,974**	**871,841**	**–794,652**	**80,163**

Consolidated statement of cash flows in summary

Amounts in SEK thousand	2026 Jul–Sep	2025 Jul–Sep	2026 Jan–Sep	2025 Jan–Sep	2025 Jan–Dec
Operating activities					
Operating result	–12,944	–17,171	–18,919	–71,537	–93,398
Adjustment for items not included in the cash flow	219	–4,206	66	–1,973	7,562
Interest	0	315	1	952	1,375
Paid interest	–36	915	–2,743	–11,639	–12,503
Cash flow from operating activities before changes in working capital	**–12,761**	**–20,146**	**–21,596**	**–84,197**	**–96,963**
Cash flow from changes in working capital					
Change in operating receivables	7,381	804	–8,214	4,415	5,679
Change in operating liabilities	–5,582	24,600	–23,276	48,745	36,064
Cash flow from operating activities	**–10,962**	**5,259**	**–53,086**	**–31,037**	**–55,220**
Investment activities					
Acquisition of tangible fixed assets	–	–	–	–	–
Cash flow from investment activities	**–**	**–**	**–**	**–**	**–**
Financing activities					
New financial debts	–	–	–	18,795	18,795
Amortization of financial liabilities, loan debt	–5,228	–16,530	–11,228	–16,530	–16,530
Amortization of financial liabilities, leasing debt	–891	–833	–2,630	–2,572	–3,419
Rights issue	72,510	74,560	72,510	74,560	74,560
Proceeds from warrant premiums	198	–	198	–	–
Cash flow from financing activities	**66,588**	**57,196**	**58,850**	**74,252**	**73,405**
Cash flow for the period	**55,626**	**56,488**	**5,764**	**43,215**	**18,185**
Cash and cash equivalents at the start of the period	34,218	53,644	81,859	66,917	66,917
Unrealized exchange rate effects on foreign currency bank accounts.	797	–	3,019	–	–3,243
Cash and cash equivalents at the end of the period	**90,641**	**110,132**	**90,641**	**110,132**	**81,859**

Parent company income statement in summary

Amounts in SEK thousand	2026 Jul–Sep	2025 Jul–Sep	2026 Jan–Sep	2025 Jan–Sep	2025 Jan–Dec
Operating income					
Net revenue	1,641	1,497	4,081	4,437	5,880
Total income	*1,641*	*1,497*	*4,081*	*4,437*	*5,880*
Operating expenses					
Other external costs	–1,936	–1,531	–5,157	–6,209	–8,248
Personnel costs	–3,727	–2,693	–9,646	–10,036	–13,331
Other operating expences	-	-	-	-	1
Total operating expenses	*–5,663*	*–4,224*	*–14,803*	*–16,245*	–21,578
Operating result	***–4,023***	***–2,727***	***–10,722***	***–11,808***	***–15,698***
Result from financial items					
Results from impairment losses in group companies	-10,000	-	-17,500	-60,257	-100,257
Interest income	101	62	131	269	333
Interest costs	-499	-3,290	-5,090	-15,619	-17,601
Total financial items	*-10,399*	*-3,228*	*-22,459*	*-75,607*	*-117,524*
Result after financial items	***–14,421***	***–5,956***	***–33,181***	***–87,415***	***–133,222***
Tax on the period's result	-	-	-	-	-
Result for the perioden	**–14,421**	**–5,956**	**–33,181**	**–87,415**	**–133,222**

Parent company statement of comprehensive income in summary

Amounts in SEK thousand	2026 Jul–Sep	2025 Jul–Sep	2026 Jan–Sep	2025 Jan–Sep	2025 Jan–Dec
Profit/loss for the period	–14,421	–5,956	–33,181	–87,415	–133,222
Other comprehensive income	-	-	-	-	-
Comprehensive income for the period	**–14,421**	**–5,956**	**–33,181**	**–87,415**	**–133,222**

Parent company balance sheet in summary

Amounts in SEK thousand	09/30/2026	09/30/2025	12/31/2025
ASSETS			
Fixed assets			
Financial fixed assets			
Shares in group companies	350,320	350,320	350,320
Total fixed assets	**350,320**	**350,320**	**350,320**
Current assets			
Other receivables	2,064	31,801	2,019
Cash and cash equivalents	53,827	38,407	23,186
Total current assets	**55,891**	**70,208**	**25,205**
TOTAL ASSETS	**406,212**	**420,528**	**375,525**
EQUITY AND LIABILITIES			
Equity			
Restricted equity			
Share capital	2,974	1,699	1,699
	2,974	*1,699*	*1,699*
Unrestricted equity			
Share premium fund	917,524	846,091	846,091
Retained earnings including total result for the period	−537,168	−458,179	−503,987
Total Unrestricted equity	*380,356*	*387,912*	*342,105*
Total equity	**383,331**	**389,611**	**343,804**
Long-term liabilities			
Interest bearing debts, loan	17,028	25,422	-
Total long-term liabilities	**17,028**	**25,422**	**-**
Short-term liabilities			
Interest bearing debts, loan	-	-	26,416
Other liabilities	5,853	5,496	5,306
Total short-term liabilities	**5,853**	**5,496**	**31,721**
TOTAL EQUITY AND LIABILITIES	**406,212**	**420,528**	**375,525**

Key financial ratios for the group

	2026 Jan-Sep	2025 Jan-Sep	2025 Jan-Dec	2024 Jan-Dec	2023 Jan-Dec
Net sales, SEK thousand	52,696	42,739	57,462	94,628	5,678
Operating profit/loss, SEK thousand	-18,919	-71,537	-93,398	-75,111	-180,765
Profit/loss for the period, SEK thousand	-23,264	-86,518	-110,010	-83,129	-177,839
Profit/loss attributable to the parent company's shareholders, SEK thousand	-23,264	-86,518	-110,010	-83,129	-177,839
Earnings per share before and after dilution, SEK	-0.22	-1.42	-1.64	-1.60	-3.43
R&D costs, SEK thousand	60,417	99,774	130,786	163,669	151,312
R&D costs as a percentage of operating expenses, %	80	83	84	87	81
Cash and cash equivalents at the end of the period, SEK thousand	90,641	110,132	81,859	66,917	111,309
Cash flows from operating activities, SEK thousand	-53,086	-31,037	-55,220	-65,590	-164,850
Cash flows for the period, SEK thousand	5,764	-43,215	18,185	-44,394	-141,467
Equity, SEK thousand	80,163	54,210	30,718	32,635	115,764
Equity attributable to the parent company's shareholders, SEK thousand	80,163	54,210	30,718	32,635	115,764
Equity per share, SEK	0.54	0.64	0.36	0.63	2.23
Equity ratio, %	52	32	22	24	65
Average number of employees	30	31	32	32	31
Average number of employees in R&D	26	28	28	27	26

Of the key financial ratios above, Earnings per share before and after dilution is the only key financial ratio that is mandatory and defined in accordance with IFRS. Of the other key financial ratios, Profit/loss for the period, Cash and cash equivalents at the end of the period, Cash flows from operating activities, Cash flows for the period, and Equity were obtained from a financial statement defined by IFRS. For the derivation of key financial ratios, as well as definitions and justifications for the selected key financial ratios, please refer to the IRLAB Therapeutics AB 2025 Annual Report.

Other information

Accounting principles

This interim report has been prepared in accordance with IAS 34, Interim Financial Reporting, and the applicable provisions of the Swedish Annual Accounts Act. Disclosures required under IAS 34 are presented both in the notes and elsewhere in the interim report. The Parent Company's financial statements have been prepared in accordance with the Swedish Annual Accounts Act and RFR 2, Accounting for Legal Entities. The accounting policies applied are consistent with those described in the Annual Report for 2025. The value of the warrants has been determined using the Black-Scholes valuation model.

The preparation of financial statements in accordance with IFRS requires the use of certain critical accounting estimates. It also requires management to exercise judgment in applying the Company's accounting policies. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to the financial statements, are disclosed in Note 4 of the 2025 Annual Report. No new standards, amendments to standards, or interpretations effective in 2026 that are expected to have a material impact on IRLAB's financial reporting have been identified.

Upcoming Accounting Requirements – IFRS18

IFRS 18 and related amendments to other standards are effective for financial years beginning on or after 1 January 2027, with retrospective application. The new standard, which has been adopted by the EU, replaces IAS 1. Its purpose is to enhance the usefulness of financial statements by increasing comparability across entities and ensuring that sufficient detailed information is provided without obscuring material information with immaterial disclosures. The implementation of IFRS 18 will not affect the recognition or measurement of items in the financial statements but will result in changes to presentation and disclosures, including management-defined performance measures.

Based on the Group's preliminary assessment, IFRS 18 will have a limited impact on the presentation of the consolidated statement of profit or loss and statement of cash flows, as certain transactions will be reclassified between categories and additional disclosures regarding MPMs will be required. No material impact is expected on the presentation of the consolidated statement of financial position.

Transactions with related parties

IRLAB has during the period January 1 - September 30, 2026 paid salaries and other remuneration to the executive management and board fees to the board, in accordance with the resolution of the Annual General Meeting. During the period, IRLAB also paid compensation to a company related to Chairman Jan-Fredrik (Janne) Backman. These transactions were not considered material to either IRLAB or the recipient and were conducted on arm's-length terms.

Revenue January – September 2026

Net sales consist of revenue from services related to ongoing studies, invoicing of work performed on behalf of customers and other service revenue. Service revenue consists of a milestone from Otsuka of 3 million USD, corresponding to SEK 27,101k, and service revenue of SEK 25,595k related to compensation for work performed on behalf of customers.

Net sales by revenue category	2026 Jan–Sep	2025 Jan–Sep	2025 Jan–Dec
Service revenue	52,696	42,739	57,462
Total revenue	**52,696**	**42,739**	**57,462**

Segment information

Net sales by geographic market	2026 Jan–Sep	2025 Jan–Sep	2025 Jan–Dec
Danmark	450	-	-
USA	52,246	42,739	57,462
Total revenue	**52,696**	**42,739**	**57,462**

Invoicing was in Swedish kronor (SEK) and American dollars (USD). Revenue is recognized in Swedish krona (SEK). In the tables above, all amounts are in thousand SEK.

Risks and uncertainties

Research and development activities within the pharmaceutical industry involve significant risks, the effects of which on the Company's earnings and financial position cannot always be controlled by the Company. Consequently, in evaluating IRLAB's future potential, it is important to consider not only the opportunities presented by the Company's projects and operations, but also the associated risks. IRLAB's business model entails substantial development costs, with potential revenue from licensing agreements, asset sales or partnerships generally arising only after a substantial portion of the development process has been completed.

The Company's business and financial risks are described on pages 89-91 of the 2025 Annual Report, while risk management is described on pages 130-131. No material changes have occurred that affect the risks previously disclosed.

The wars in Ukraine and the Middle East, together with the resulting geopolitical instability in surrounding regions, may affect the pace of patient recruitment. IRLAB's ongoing Phase Ib study of linepemat (IRL757) is expected to be conducted in areas geographically close to Ukraine, which could present a potential risk of disruptions to patient recruitment. However, only limited effects have been observed in previous studies, and

developments are being monitored continuously in order to implement appropriate measures if required.

The continued uncertainty in the United States, characterised by economic volatility, trade policy tensions and the U.S. conflict with Iran, contributes to increased volatility in global capital markets. For a research-driven company without marketed products, both financing and operations may be affected by changes in the investment climate, the supply of research materials and uncertainty in regulatory processes. These factors may also complicate or delay discussions and agreements with potential collaboration partners.

Forward-Looking Statement

This report contains forward-looking statements that reflect the current views of the Board of Directors and management regarding future events and financial and operational performance. While the Board of Directors and management consider the expectations presented in this report to be reasonable, no assurance can be given that such expectations will prove to be correct. Accordingly, actual results may differ materially from those expressed or implied in the forward-looking statements as a result of various factors, including, but not limited to, changes in economic conditions, market developments, legislative and regulatory requirements, political decisions and actions, and fluctuations in exchange rates.

Employees

During the quarter, work corresponding to 28 (31) full-time equivalent employees was performed. This work was carried out by 28 (32) individuals. In addition, the Company engages a number of consultants in key functions who work full-time or part-time for IRLAB.

Annual General Meeting

The 2027 Annual General Meeting is planned to be held on 3 June 2027 in Gothenburg. To have a matter considered at the Meeting, a shareholder request must be received by the Company no later than 15 April 2027. Such requests should preferably be submitted to ir@irlab.se.

Nomination Committee for the 2027 Annual General Meeting

The Nomination Committee for the 2027 Annual General Meeting comprises Daniel Johnsson (Chair), Joakim Tedroff, Patrik Mossberg and Janne Backman, Chairman of the Board of IRLAB Therapeutics AB (publ). For further information, please refer to the press release dated 20 October 2026 and www.irlab.se/corporate-governance/nomination-committee 2027.

Sustainability

IRLAB's sustainability work is based on the UN Sustainable Development Goals that are essential to the business and where the company may make the greatest difference: gender equality, decent working conditions and economic growth, sustainable industry, innovations and infrastructure, and responsible consumption and production. IRLAB summarizes its sustainability efforts in the following three focus areas: Employees, Responsible dealings, Community involvement.

Significant events during the period

In January, IRLAB entered into a collaboration agreement with the Danish biotech company Biomia ApS to evaluate Biomia's drug candidates using IRLAB's research platform, the Integrative Screening Process (ISP).

In mid-February, the company announced that it had received scientific advisory board confirmation on the next steps in the development of pirepemat.

In February, the Company announced that it had secured a milestone payment of USD 3 million following the dosing of the first patient in the Phase Ib study, LIFT-PD, of linepemat (IRL757) in Parkinson's disease.

In March, the Company presented clinical and preclinical data at AD/PD™ 2026–the 20th International Conference on Alzheimer's and Parkinson's Diseases.

In April, the nomination committee proposed the election of Jan-Fredrik Backman as new Vice Chairperson and James Gamgort as new Board member at the Annual General Meeting in 2026 and in addition re-election of Chairperson Carola Lemne and Board members Gunnar Olsson, Rein Piir and Veronica Wallin. Christer Nordstedt has declined re-election.

In May, the Board of Directors resolved on a rights issue of approximately SEK 68 million, consisting of Class A shares, with an over-allotment issue of approximately SEK 33.8 million, subject to approval by the extraordinary general meeting. In connection with the share issue, the Company announced that the the term for SEK 18.5 million of the outstanding loan of SEK 23.7 million from Fenja Capital has been extended to 30 November 2027. The remaining SEK 5.2 million is to be repaid in connection with the completion of the rights issue.

In May, the Board of Directors resolved to convene an Extraordinary General Meeting on 5 June 2026 to approve the proposed share issue, resolve on an amendment to the Articles of Association, and elect new members to the Board of Directors.

In May, the company published the communiqué from the Extraordinary General Meeting. All proposed resolutions were approved by the meeting. In accordance with the Nomination Committee's proposal, the meeting elected Jan-Fredrik Backman and James Gamgort as new members of the Board of Directors.

In June, the company announced that it will present an integrated analysis of clinical data for mesdopetam at the international conference StanCon 2026. The analysis confirms robust efficacy results from the Phase II clinical studies.

In June, the company announced the outcome of the rights issue. With a subscription rate of approximately 112.6%,

the company raised approximately SEK 68 million before deduction of transaction costs. As the rights issue was oversubscribed, the company received an additional approximately SEK 8.6 million through an over-allotment issue, before deduction of issue-related costs. Consequently, the company raised a total of approximately SEK 76.5 million through the rights issue and the over-allotment issue, before deduction of issue-related costs.

In June, the company published the communiqué from the Annual General Meeting. All proposed resolutions were approved by the meeting. Christer Nordstedt stepped down from the Board of Directors in connection with the AGM. Following the meeting, the Board consists of Carola Lemne (Chairperson), Jan-Fredrik Backman (Vice Chairperson), James Gamgort, Gunnar Olsson, Rein Piir, and Veronica Wallin.

In July, the Company announced that the registered number of shares and votes in IRLAB Therapeutics AB had increased as a result of the rights issue of Class A shares. As of 31 July 2026, the total number of shares in IRLAB amounted to 146,461,921, of which 146,382,145 were Class A ordinary shares and 79,776 were Class B ordinary shares, each carrying one (1) vote.

In August, the Company announced that the World Health Organization (WHO) had assigned the drug candidate IRL757, which is being developed as a potential first-in-class treatment for apathy, the International Nonproprietary Name (INN) linepemat.

In August, the Company announced that the registered number of shares and voting rights in IRLAB Therapeutics AB had increased as a result of the rights issue and overallotment issue of Series A shares. As of 31 August 2026, the total number of shares in IRLAB amounted to 148,711,921, of which 148,632,145 were Series A ordinary shares and 79,776 were Series B ordinary shares, each carrying one (1) vote.

In September, the CEO announced her intention to step down during the first quarter of 2027.

At the end of September, the Company announced that Jan-Fredrik (Janne) Backman had assumed the position of Chair of the Board of Directors. Janne was elected Vice Chair of the Board at the 2026 Annual General Meeting.

Significant events after the period

In October, the Company announced that research supporting linepemat had been published in the scientific journal Bioorganic & Medicinal Chemistry Letters.

In November, the Company announced that the US Patent and Trademark Office (USPTO) intends to grant a patent for the Company's drug candidate IRL1117.

In November, the company announced that IRLAB will strengthens focus on revenue generation, initiates workforce reductions, and announces reduced likelihood of new partnership agreements in 2026.

Review by the auditors

The swedish report has been reviewed by the company's auditors.

Board's assurance

The Board of Directors and the CEO assure that the interim report provides a fair overview of the parent company's and the group's operations, position and results and describes significant risks and uncertainties faced by the company and group companies.

Gothenburg, November 13, 2026

JAN-FREDRIK BACKMAN Chair of the Board	GUNNAR OLSSON Board member
JAMES GAMGORT Board member	REIN PIIR Board member
VERONICA WALLIN Board member	KRISTINA TORFGÅRD Chief Executive Officer

Auditor's report

This is a translation of the Swedish language original

IRLAB Therapeutics AB (publ.) reg. no. 556931-4692

Introduction

We have reviewed the condensed interim financial information interim report of IRLAB Therapeutics AB as of 30 September 2026 and the nine-month period then ended. The board of directors and the CEO are responsible for the preparation and presentation of the interim financial information in accordance with IAS 34 and the Swedish Annual Accounts Act. Our responsibility is to express a conclusion on this interim report based on our review.

Scope of Review

We conducted our review in accordance with the International Standard on Review Engagements ISRE 2410, Review of Interim Report Performed by the Independent Auditor of the Entity. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing, ISA, and other generally accepted auditing standards in Sweden. The procedures performed in a review do not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the interim report is not prepared, in all material respects, in accordance with IAS 34 and the Swedish Annual Accounts Act, regarding the Group, and with the Swedish Annual Accounts Act, regarding the Parent Company.

Material uncertainty related to going concern

We would like to draw the reader's attention to the information provided in the interim report under the section "Financial position". It states that the company is dependent on liquidity injection to be able to continue its operations. This matter gives rise to material uncertainty which may cast significant doubt on the entity's ability to continue as a going concern.We have not modified our conclusion in respect of that matter.

Signatures on Swedish original.

Öhrlings PricewaterhouseCoopers AB

ULRIKA RAMSVIK
Authorized Public Accountant
Auditor in charge

SOPHIE DAMBORG
Authorized Public Accountant

Glossary

API
API stands for Active Pharmaceutical Ingredient, and it refers to the primary ingredient in a medication that provides its therapeutic effect.

CNS disorders
Central Nervous System (CNS) disorders are a broad category of conditions in which the brain does not function as it should, leading to a decline in health and the ability to function.

CRO
Clinical Research Organization (CRO) conducts clinical studies on behalf of biotech companies that may not have the internal capacity, as in larger pharmaceutical companies.

Drug Product
Refers to the medication to be used in clinical trials. The Drug Product contains Active Pharmaceutical Ingredients (API) and additional ingredients to ensure beneficial properties of the entire medication, such as bioavailability, proper shelf life, stability, or formulations with slow release.

End-of-Phase 2 meeting
The purpose of an end-of-Phase 2 meeting is to determine the safety of proceeding to Phase III, to evaluate the Phase III plan and protocols and the adequacy of current studies and plans, and to identify any additional information necessary to support a marketing application for the uses under investigation.

GMP manufacturing
GMP stands for Good Manufacturing Practice, which describes how pharmaceutical companies should manufacture drug substances to ensure that regulatory authorities and patients can always be confident they are receiving the right product of high quality.

ISP
Integrative Screening Process (ISP) is IRLAB's proprietary research platform used to generate drug candidates.

Proof of concept
A critical phase in which one evaluates whether a drug candidate exhibits the desired biological effect in humans, usually through a small clinical study. The goal of Proof of Concept is often to show that the drug candidate has the potential to treat the disease or condition it is targeting, before more extensive and costly clinical trials are initiated.

IRLAB

IRLAB discovers and develops a portfolio of transformative treatments for all stages of Parkinson's disease. The company originates from Nobel Laureate Prof Arvid Carlsson's research group and the discovery of a link between brain neurotransmitter disorders and brain diseases. Mesdopetam (IRL790), under development for treating levodopa-induced dyskinesias, has completed Phase IIb and is in preparation for Phase III. Pirepemat (IRL752), currently in Phase IIb, is being evaluated for its effect on fall frequency in Parkinson's disease. Linepemat (IRL757), a compound being developed for the treatment of apathy in neurodegenerative disorders, is in Phase Ib. In addition, the company is also developing two preclinical programs, IRL942 and IRL1117, towards Phase I studies. IRLAB's pipeline has been generated by the company's proprietary systems biology-based research platform Integrative Screening Process (ISP). Headquartered in Sweden, IRLAB is listed on Nasdaq Stockholm (IRLAB A).

Contact information

FOR FURTHER INFORMATION, PLEASE CONTACT:

Kristina Torfgård, CEO
+46 730 60 70 99
kristina.torfgard@irlab.se

Gustaf Albèrt, CFO
+46 709 16 83 02
gustaf.albert@irlab.se

HEAD OFFICE

IRLAB Therapeutics AB, Corporate identity No. 556931-4692
Arvid Wallgrens Backe 20
413 46 Gothenburg
Sweden
+46 31 757 38 00
www.irlab.se
info@irlab.se